Search Results - Bourquelot, Priscille M.

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

    Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma by Wolf, Jeffrey L., Siegel, David, Goldschmidt, Hartmut, Hazell, Katharine, Bourquelot, Priscille M., Bengoudifa, Bourras R., Matous, Jeffrey, Vij, Ravi, de Magalhaes-Silverman, Margarida, Abonour, Rafat, Anderson, Kenneth C., Lonial, Sagar

    Published in Leukemia & lymphoma
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma

    A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma by San-Miguel, Jesús F., Sezer, Orhan, Siegel, David, Guenther, Andreas, Mateos, Maria-Victoria, Prosser, Ian, Cavo, Michele, Blade, Joan, Boccadoro, Mario, Bengoudifa, Bourras R., Klebsattel, Martin, Bourquelot, Priscille M., Anderson, Kenneth C.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

    A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibi... by Guilhot, François, Dubruille, Viviane, Skotnicki, Aleksander B., Hellmann, Andrey, Shamsazar, Jila, Bourquelot, Priscille M., Jalaluddin, Muhammad, Li, Martha, Abruzzese, Elisabetta, Akard, Luke

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ≥2 BCR-ABL Tyrosine Kinase Inhibitors

    A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ≥2 BCR-ABL Tyrosine Kinase Inhibitors by Zaritskey, Andrey, Alimena, Giuliana, Konopka, Lech, Shamsazar, Jila, Bourquelot, Priscille M., Jalaluddin, Muhammad, Li, Martha, Turkina, Anna, Ossenkoppele, Gert J., Goldberg, Stuart L., Powell, Bayard

    Published in Blood
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma

    A Phase IB, Multicenter, Open-Label, Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma by Siegel, Davi d, Sezer, Orhan, San Miguel, Jesus F., Mateos, Maria-Victoria, Prosser, Ian, Cavo, Michele, Jalaluddin, Muhammad, Hazell, Katharine, Bourquelot, Priscille M., Anderson, Kenneth C.

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

    A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma by Wolf, Jeffrey Lee, Siegel, David, Matous, Jeffrey, Lonial, Sagar, Goldschmidt, Hartmut, Schmitt, Stefan, Vij, Ravi, De Malgalhaes-Silverman, Margarida, Abonour, Rafat, Jalaluddin, Muhammad, Li, Martha, Hazell, Katharine, Bourquelot, Priscille M., Mateos, Maria-Victoria, Anderson, Kenneth C., Spencer, Andrew, Harousseau, Jean-Luc, Bladé, Joan

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients

    Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients by Moreau, Philippe, Leblond, Véronique, Bourquelot, Priscille, Facon, Thierry, Huynh, Anne, Caillot, Denis, Hermine, Olivier, Attal, Michel, Hamidou, Mohamed, Nedellec, Gérard, Ferrant, Augustin, Audhuy, Bruno, Bataille, Régis, Milpied, Noël, Harousseau, Jean‐Luc

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  8. 8
    Essential thrombocythaemia: a cause of Sneddon's syndrome

    Essential thrombocythaemia: a cause of Sneddon's syndrome by Michel, Marc, Bourquelot, Priscille, Hermine, Olivier

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  9. 9
    TAL1 expression does not occur in the majority of T‐ALL blasts

    TAL1 expression does not occur in the majority of T‐ALL blasts by Delabesse, Eric, Bernard, Muriel, Meyer, ValÉrie, Smit, Linda, Pulford, Karen, Cayuela, Jean‐Michel, Ritz, Jermoe, Bourquelot, Priscille, Strominger, Jack L., Valensi, FranÇoise, Macintyre, Elizabeth A.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  10. 10
    Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization

    Simultaneous detection of MYC, BVR1, and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization by Rack, Katrina, Delabesse, Eric, Radford-Weiss, Isabelle, Bourquelot, Priscille, Le Guyader, Gaëlle, Vekemans, Michel, Macintyre, Elizabeth

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: